Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHEREXA: trastuzumab + capecitabine with or without pertuzumab in HER2-positive metastatic breast cancer
2008-006801-17Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of pertuzumab in HER2-enriched breast cancer (HER2+) (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival (IRF-assessed). Started Jul 2009; status: completed.
02
Drugs
pertuzumab
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2008-006801-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006801-17.